Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer
The Prostate · 2026-06 · 86 (9) · 1028-1034
DOI: 10.1002/pros.70181 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 15.04.2026. Verfasst von Sudharshanan Balaji und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cryosurgery, Salvage Therapy, Neoplasm Recurrence, Local. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
To report long‐term oncologic and functional outcomes of a second therapeutic freeze (STF) after salvage cryoablation (sCryo) for biopsy‐proven persistence following radiotherapy for localized prostate cancer. Patients and Methods We retrospectively reviewed 10 men with biopsy‐proven local recurrence after sCryo following radiotherapy who underwent a STF. Outcomes were urinary and erectile function (social continence 0–1 pad/day; potency defined as International Index of Erectile Function‐5 (IIEF‐5) score ≥ 17), complications (Clavien–Dindo classification), and oncologic endpoints: failure‐free survival (FFS), metastasis‐free survival (MFS), cancer‐specific survival (CSS), and overall survival (OS). FFS was defined as the absence of Phoenix biochemical failure, radiographic progression, initiation of systemic therapy, or prostate cancer‐specific death. MFS, CSS, and OS were time‐to‐event endpoints, estimated using Kaplan–Meier methods.
Results
Median follow‐up was 77 months (Interquartile range [IQR] 37–133). The median interval between the cryoablations was 22 months (IQR 10–33). At 5 years, FFS was 52.5% (95% CI 15.0–80.4), MFS was 80.0% (95% CI 40.9–94.6), CSS was 87.5% (95% CI 38.7–98.1), and OS was 75.0% (95% CI 31.5–93.1). Median ADT/systemic‐therapy deferral after STF was 19 months (IQR 9–42.5). After STF, 7/10 men were socially continent; and 6/10 were pad‐free at 1 year. Both men who were potent pre‐STF, remained potent. No Clavien–Dindo ≥ III complications were attributable to STF, though a rectourethral fistula was observed at 5 months post‐STF in a single patient.
Conclusion
In this limited cohort with intermediate‐ to long‐term follow‐up, STF after prior sCryo preserved genitourinary function and deferred ADT in select men with local recurrence after radiation and sCryo. While oncological outcomes are not equivalent to primary treatment, STF appears to be a feasible and reasonably safe option to extend local control in carefully selected candidates. Larger, prospective studies are needed before broader conclusions can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Duke University Medical Center, Durham, North Carolina, USA.
- Center for Prostate and Urologic Cancers, Duke Cancer Institute, Durham, North Carolina, USA.
- Institute for Medical Research, Veteran Affairs Medical System, Durham, North Carolina, USA.
- Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Sudharshanan Balaji, Mahdi Mottaghi, Paul P Koffer, Thomas J Polascik
Zitieren
APA
Balaji, S., Mottaghi, M., Koffer, P. P., & Polascik, T. J. (2026). Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer. The Prostate, 86(9), 1028-1034. https://doi.org/10.1002/pros.70181
Vancouver
Balaji S, Mottaghi M, Koffer PP, Polascik TJ. Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer. The Prostate. 2026;86(9):1028-1034. doi:10.1002/pros.70181
BibTeX
@article{Balaji2026,
author = {Balaji, Sudharshanan and Mottaghi, Mahdi and Koffer, Paul P and Polascik, Thomas J},
title = {Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {9},
pages = {1028--1034},
doi = {10.1002/pros.70181}
}
EUVIMED